Cargando…
Pediatric hereditary angioedema
Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical sympto...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282351/ https://www.ncbi.nlm.nih.gov/pubmed/24313851 http://dx.doi.org/10.1111/pai.12168 |
_version_ | 1782351120392257536 |
---|---|
author | MacGinnitie, Andrew J |
author_facet | MacGinnitie, Andrew J |
author_sort | MacGinnitie, Andrew J |
collection | PubMed |
description | Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical symptoms. In addition to the physical symptoms, patients experience significant decrements in vocational and school achievement as well as in overall quality of life. Symptoms often begin in childhood and occur by age 20 in most patients, but life-threatening attacks are uncommon in the pediatric population. The availability of new therapies has transformed the management of HAE. |
format | Online Article Text |
id | pubmed-4282351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42823512015-01-15 Pediatric hereditary angioedema MacGinnitie, Andrew J Pediatr Allergy Immunol Review Articles Hereditary angioedema (HAE) is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, ominously, the upper airway. It is caused by inadequate activity of the protein C1-inhibitor, with dysfunction in the kallikrein/bradykinin pathway underlying the clinical symptoms. In addition to the physical symptoms, patients experience significant decrements in vocational and school achievement as well as in overall quality of life. Symptoms often begin in childhood and occur by age 20 in most patients, but life-threatening attacks are uncommon in the pediatric population. The availability of new therapies has transformed the management of HAE. BlackWell Publishing Ltd 2014-08 2013-12-09 /pmc/articles/PMC4282351/ /pubmed/24313851 http://dx.doi.org/10.1111/pai.12168 Text en © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles MacGinnitie, Andrew J Pediatric hereditary angioedema |
title | Pediatric hereditary angioedema |
title_full | Pediatric hereditary angioedema |
title_fullStr | Pediatric hereditary angioedema |
title_full_unstemmed | Pediatric hereditary angioedema |
title_short | Pediatric hereditary angioedema |
title_sort | pediatric hereditary angioedema |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282351/ https://www.ncbi.nlm.nih.gov/pubmed/24313851 http://dx.doi.org/10.1111/pai.12168 |
work_keys_str_mv | AT macginnitieandrewj pediatrichereditaryangioedema |